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A B S T R A C T
Upon cardiac implantable electronic device (CIED) exchange, upgrade, or revision surgery patients are exposed
to a considerable risk of adverse events. The presence of ﬁrm ﬁbrotic tissue endangers these procedures. Leads
can be damaged in the attempt of freeing them from ﬁbrotic tissue. Hematoma can form as result of capsu-
lectomy, pocket debridement and leads dissection. Due to the increasing number of CIED exchange, upgrade and
revision surgeries, the incidence of related complications is expected to rise in the near future.The aim of the
study was to evaluate the feasibility, safety, and performance of a rationally micro-engineered non-resorbable
biosynthesized cellulose (BC) membrane as conformal wrapping protection around CIED implants. Protective
membranes were generated by means of a recently established method to transfer on-demand microscale geo-
metries onto the surface of BC. A chronic minipig animal model was selected to investigate the performance of
the BC anti-ﬁbrotic protection, directly measured as reduction of ﬁbrotic tissue formation. Sixteen (n=16)
animals received each one BC coated pacemaker (PMC) and one native pacemaker (BI) at equivalent anatomical
sites. BC protective layers were juxtaposed around pacemakers through a fast and well-repeatable procedure.
Explants were performed at 3 and 12 months after implantation. Endpoint analysis showed that the BC pro-
tective layers were 100% integer, with no sign of chemical or mechanical degradation and appeared as a thin
layer of white-tan material, adherent to the surrounding thin ﬁbrous capsule, from which it could be peeled oﬀ
by gently pulling with forceps. The protective eﬀect of micro-engineered BC yielded an average thickness re-
duction of 66% of the ﬁbrotic tissue thickness generated around PMC, as compared to that measured around the
naked counterpart (i.e. the BI). When protected by in BC, both the generator and the proximal parts of the leads
were completely free from ﬁbrotic tissue. The insertion of an anti-adhesive, non-resorbable and well-tolerated
BC interface between the implant and the surrounding tissue in the surgical pocket signiﬁcantly reduced the
formation of ﬁbrotic tissue, ensuring an easy access to the device pocket, and thus creating the conditions for
simpliﬁed CIED revision surgeries.
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1. Introduction
The annual number of cardiac implantable electronic device (CIED)
implantations has nearly doubled in the last 15 years, to about 2 million
devices implanted annually worldwide [1]. The growth is explained by
the introduction of cardiac resynchronization therapy and an increased
use of implantable cardioverter deﬁbrillators (ICDs) [2,3]. In the frame
of an ageing Western population, these ﬁgures are bound to further rise
[4].
Despite the high functional performance of current CIEDs, im-
portant drawbacks are connected to their implantation. Lead related
complications account for approximately 30% of all adverse events
recorded within 6 months after implantation [5]. Problems at the
generator pocket (e.g. lead damage, pocket hematoma), although un-
derrepresented in scientiﬁc literature, occur with similar incidence [5].
Risks related to generator replacement procedures are frequently un-
derestimated. In this direction, a recent prospective multicentre study
has clearly demonstrated that device replacement is associated with a
considerable threat of major and minor adverse events [6].
A common source of complications is ﬁbrotic adhesion, generated in
and around the surgical pocket as a result of foreign body reaction
[7,8]. The sequence of events leading to the deposition of ﬁbrotic tissue
starts immediately after device implantation, and is sustained over
weeks to months by the engagement and activation of ﬁbroin-
ﬂammatory cell mediators and actuators [9]. Upon revision surgery, the
necessity to free the device as well as the leads from the embedding
tissue exposes to the risk of lead damage and in such cases escalating
the procedure to a full lead revision surgery [10]. In addition, a thick
ﬁbrotic tissue may negatively inﬂuence the conditions for the onset of
local infections, enforcing a barrier with low vascularization and poorly
conducive to circulating immune cells. This renders infections at the
implant interface signiﬁcantly more likely during the generator ex-
change, device upgrade or revision procedures [11] than upon de novo
implantations [12]. In this scenario, a healthy regeneration of the tis-
sues lining the surgical pocket is essential to lower the risk of such
procedures and/or revision and avoid pocket infections. A universal
solution to this problem is still missing, representing an unmet clinical
need connected to CIED implantation procedures.
Bacterial cellulose (BC) has emerged as a well-tolerated and stable
hydrogel material for biomedical applications [13,14]. The strong hy-
drophilicity of cellulose nanoﬁbers confers antifouling properties to the
surface of BC layers [15]. In addition, the interaction with human cells
is modulated by the implementation of optimized microscale topo-
graphies [16,17].
Much information regarding the biological eﬀect of rationally-de-
veloped surface geometries has been reported for implant materials of
diﬀerent nature, including metals, elastomers, plastic polymers and
others [18–20]. In general, topographic features with lateral and ver-
tical size of few microns are able to physically interfere with the es-
tablishment and maturation of integrin contacts, thereby promoting or
demoting cell adhesion, migration and diﬀerentiation [21,22]. While
anisotropic textures, in the form of gratings, facilitate cell spreading
and polarization [23] symmetric arrays of isotropic features have the
opposite eﬀect, bestowing anti-adhesive properties to the target sub-
strate [24].
Surface geometries are introduced on BC by a lithographic protocol
harnessing the fermentation process [25]. Speciﬁcally, symmetric ar-
rays of hexagonal pits in the micron range interfere with the adhesion
of cells involved in foreign body reaction, including ﬁbroblasts and
macrophages [24]. A parametric optimization of the pit dimensions and
Fig. 1. SEM imaging of implanted micro-structured bio-synthetized cellulose (BC) and surgical procedure used to test the BC coating membrane: a) Fibrous structure
of BC. Scale bar 2 μm. b) Micro-well pattern on BC surface. Representative area homogeneously structured. Top-right inset detail of the micro-wells, where the ﬁbrous
structure of the material is evident. Bottom-left inset top-view schematic of the layout of the micro wells on the surface. Red circles represent the micro-wells, solid
black line depicts the hexagonal arrangement of the features and the blue dashed line highlights the elemental cell shaped as an equilateral triangle with 10 μm side
length. Scale bar 300 μm. Scale bar in the inset 5 μm. c) Graphic ﬂowchart of the entire surgical procedure. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article.)
F. Robotti, et al. Biomaterials 229 (2020) 119583
2
spatial arrangement renders BC substrates that signiﬁcantly hamper the
adhesion and diﬀerentiation of the cellular mediators and actuators of
ﬁbrosis [24].
In the present study, we describe the design, development and in
vivo translation of a surface-engineered BC membrane representing an
anti-ﬁbrotic protection at the interface between CIED devices and the
surgical pocket. The application of this new medical device reduced
signiﬁcantly the formation of ﬁbrotic tissue in a large, and clinically
relevant animal (minipig) model over a period of 3 and 12 months. The
long-term analysis provides evidence of BC in vivo stability and safety
upon implantation. The anti-ﬁbrotic eﬀect is demonstrated in compar-
ison with identical procedures of bare implant (BI) deployment. Non-
invasive measurements are presented to showcase the material stability
and exclude interference with the electric function of implanted CIED
devices. Altogether, these results provide the validation of a resolutive
anti-ﬁbrotic protection, supporting its translation to the clinical appli-
cation.
2. Results
2.1. Fabrication, handling and usability of antiﬁbrotic BC membranes
Anti-ﬁbrotic membranes comprising surface microstructured BC
were generated by guided assembly biolithography (GAB [25]) using an
elastomeric mold to transfer a triangular array of hexagonal wells
(Fig. 1). Speciﬁcally, the topographical features were selected to
minimize the adhesion and diﬀerentiation of the cellular mediators and
eﬀects of foreign body reaction, i.e. monocytes and ﬁbroblasts; re-
spectively [24]. The quality of lithographic transfer and the overall
nano- and microtopography were characterized by SEM imaging
(Fig. 1a–b). Macroscopically, individual BC membranes measured
10×20 cm, showed excellent conformability (Supplementary Fig. 1)
and tensile strength (1.6 ± 0.3 N; Supplementary Fig. 2), which were
overall compatible with the suturing process.
Towards the application of the BC membranes as anti-ﬁbrotic pro-
tection surrounding BI, the typical volume increment caused by the
cloaking layer was evaluated. Speciﬁcally, the additional hindrance was
in the range of 5ml, therefore representing less than 7% of the overall
target implant volume. Consistently, the application of the BC layer did
not require a larger incision or the creation of a bigger pocket and did
not introduce any signiﬁcant modiﬁcation of the standard surgical
routine (Supplementary Fig. 3).
Another important aspect consisted in the time to apply the BC
layer, which included an initial wrapping followed by suturing with a
monoﬁlament non-resorbable Prolene suture (Fig. 1c). In general,
wrapping of the BI was reproducible (Fig. 1c and d). The surgical
procedure was completed in 46 ± 19min, as compared to
42 ± 20min in the control case of BI implantation without the BC
membrane. The increment in procedural time was not statistically sig-
niﬁcant.
2.2. Surgery and post-surgical observations
Two groups of 8 adult female minipigs (Aachener minipigs) entered
the study. A complete parametric description of the animals is reported
in the materials and methods. Each experimental animal received two
PMs, which were implanted at axisymmetric locations of the neck, as
reported in Fig. 2. In particular, a reference implant was deployed as for
the standard of care, i.e. without antiﬁbrotic protection (hereafter
identiﬁed as BI). The counterpart was wrapped with the anti-ﬁbrotic BC
membrane (hereafter identiﬁed as PMC; Fig. 1). In this case, both the
device case and a proximal segment of the leads were included in the
BC wrapping (Fig. 1c). For both implants, the distal part of the leads
was transvenously implanted in the right atrium in a regular fashion
and the device was programmed to an atrial sensing mode (OAO).
The two animal groups were sacriﬁced at 3 and 12 months after
implantation; respectively. No animal required special treatment of the
surgical wound or revision surgeries of the implantation sites. All
wounds healed without any complication. Taken together, after 3- and
12-months BC coated implants did not exhibit signs of infection or,
more in general, suboptimal surgical result. During husbandry, one
animal (included in the 12 months group) exhibited signs of back pain
and persistent lameness. It was therefore sacriﬁced before due time; i.e.
at 4 months post implantation. None of the other animals showed fever
or dysfunction, distress, disability or disorder indicating changes in
general body condition or a systemic inﬂammatory reaction throughout
the whole duration of the study (blood testing, data not shown).
Three independent approaches were adopted to gather non-invasive
measurements of the BC membrane performance. First, ultrasound
images were obtained using a high-resolution FUJIFILM Vevo 3100
ultrasound-imaging machine (18–22.5MHz transducers) to assess the
stability and conformity of the BC protection. At each time of measure
(3 and 12 months) the presence of a continuous BC membrane around
the implant was monitored. Speciﬁcally, BC appeared as a dark layer
juxtaposed to the implant. A qualitative evaluation of the tissue build-
up at the external surface of the BC membrane was performed (Fig. 2b).
Second, a computer tomography CT-scan was performed on the day of
the explant. The resulting 3D reconstruction (Fig. 2c) was used to ex-
clude implant migration and erosion of the surrounding tissues. Finally,
the electric activity of each PMC was detected and evaluated in com-
parison to the BI counterpart. Values of p-wave, voltage threshold and
impedance were registered to evaluate possible detrimental eﬀects of
cellulose wrapping on the electric functionality of the devices and are
reported in Table 1. No signiﬁcant variations in the device electric
function were detected.
2.3. Macroscopic observations
At the time of explant, all animals from both groups showed clean
surgical sutures with no sign of dehiscence and/or infection. A capsule
comprising a light beige, ﬁrm ﬁbrous tissue that anchored the devices
(Fig. 3a and b) surrounded all implants (i.e. BI and PMC). In all surgical
pockets, the ﬁbrous capsule was intact with no sign of tearing and/or
disruption. The regional lymph nodes were macroscopically un-
remarkable in both post-implantation groups.
Three-month post-implantation group. The inner surface of the BI
capsule (facing the implant) appeared smooth and well separated from
the header of the underlying devices (Fig. 3c). Less than 0.5ml of clear
ﬂuid was recovered from the device pocket hosting BI of all animals.
The BI leads, including the end of the electrodes, were embedded in a
markedly thick and ﬁrm ﬁbrous connective tissue, which hampered
their release (Fig. 3c). Therefore, in all animals, dissection or even se-
vering of the leads in multiples locations was necessary for release. On
the other hand, all animals with PMC showed intact cellulose with no
signs of degradation and/or disruption. BC appeared as a thin layer of
white-tan material with a slightly granular surface, adhered to the
surrounding ﬁbrous capsule, from which it could be easily peeled by
pulling with forceps (Fig. 3f). The leads conﬁned within the BC pocket
were free from connective tissue and could be easily removed from the
pocket in their native conﬁguration.
Twelve-month post-implantation group. The ﬁbrotic capsule around
BI showed a macroscopic morphology similar to that described at 3
months. The leads strongly adhered to the capsule through a ﬁrm and
thick ﬁbrous proliferation. Dissection or even severing of the leads was
necessary to extract the devices from the pocket (Fig. 3d). One BI
capsule (minipig 9) exhibited small amounts of ﬁbrin adhered to the
inner surface and four BI capsules (minipigs 12, 13, 14, and 15) ex-
hibited small multifocal areas of red/brown discolouration interpreted
as hemorrhages (Fig. 3d). On the other hand, all PMC pockets showed
intact BC with no signs of degradation and/or disruption. As described
at 3 months, BC appeared as a thin layer of white-tan material that
could be easily separated from the surrounding capsule (Fig. 3e).
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Fig. 2. Study schedule and summary of in vivo exams. a) schematic of the implant layout. b) High-resolution ultrasound imaging of the pacemaker covered by the
cellulose membrane. c) Schedule of the study with intermediate and ﬁnal follow up for the two study groups (group 1 and group 2, 3 and 12 months follow up,
respectively). d) CT scan of a minipig showing the positioning of the pacemakers at the 12-month follow-up.
Table 1
Electric parameters of implanted pacemakers.
Animal PMC BI
p-Wave (mV) Threshold @ 0.4 s (V) Impedance (Ω) p-Wave (mV) Threshold @ 0.4 s (V) Impedance (Ω)
1 2.8–4.0 1.75 794 0.5–0.7 0.75 427
2 4.0–5.66 2.0 130 >5.6 0.75 177
3 4.0–5.6 0.75 567 2.8–4.0 1 767
4 >5.6 1.25 635 2.8–4.0 1 590
5 >5.6 0.75 519 1.4–2.0 1.25 468
6 2.0–2.8 0.5 520 >5.6 0.25 510
7 >5.6 0.75 480 >5.6 0.75 542
8 1.4–2.0 1.5 478 >5.6 1.25 703
9 >5.6 – 470 0.7–1.0 – 470
10 0.7–1.0 – 458 2.0–2.8 – 634
11 4–5.6 0.75 426 >5.6 0.5 501
12 4–5.6 0.75 550 >5.6 0.5 475
13 2.8 1.5 567 4.0 1.0 450
14 1.3 0.75 646 3.1 0.75 589
15 2.8 1.25 754 2.8 1.0 769
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Proximal leads conﬁned within the BC pocket were not surrounded by
connective tissue and could be easily removed from the pocket
(Fig. 3e). A small amount of turbid ﬂuid (< 1ml) was detected within
the PMC device pocket of one animal (minipig 13) and another animal
exhibited small strands of ﬁbrin adhered to the device surface (minipig
14). Two animals (minipigs 9 and 14) exhibited small foci of white
discoloration at the inner surface of BC (interpreted as mineralization in
the histological examination; Supplementary Fig. 4).
2.4. Histopathological observations
The biological response to the BI and PMC devices was deﬁned by
the development of a moderately thick, well-vascularized ﬁbrotic cap-
sule surrounding the BI body and the leads. The results of the semi-
quantitative histological assessment are summarized in Table 2.
Three months post implantation. All animals developed a ﬁbrotic
capsule around the medical devices accompanied by a chronic in-
ﬂammatory response (foreign body reaction). The ﬁbrotic tissue com-
prised reactive ﬁbroblasts (showing plump nuclei) in a collagenous
stroma with moderate numbers of small calibre blood vessels (i.e. neo-
angiogenesis, Fig. 4a and b). Van Gieson's staining (VG) showed higher
amount of mature collagen ﬁbres (stained in red) in the outer layers of
the ﬁbrotic capsule compared to the mid to inner layers (stained as
yellow), which indicates the diﬀerent stages of maturation of the ﬁ-
brotic capsule (Supplementary Fig. 5). The ﬁbrotic reaction com-
pressed, inﬁltrated and replaced the neighbouring tissues, including
adipose tissue, muscle and salivary glands, which showed signs of
severe degeneration. The nature of the inﬂammatory response was si-
milar in BIs and PMCs, being dominated in both implant types by
macrophages (Iba-1+; Fig. 5a and b), moderate numbers of T-lym-
phocytes (CD3+; Fig. 5c and d) and occasional B-lymphocytes (CD20+;
Fig. 5e and f) and plasma cells. Polymorphonuclear cells, including
eosinophils, neutrophils as well as aggregates of multinucleated giant
cells (Iba-1+) were less represented. The macrophage inﬁltrates were
diﬀusely observed throughout the capsule and often showed higher
numbers in the inner regions of the capsule (close to the CIED and
cellulose) or around perivascular regions. Multinucleated giant cells
tended to form aggregates in the outer region of the capsule and rarely
inﬁltrated the inner surface (Fig. 4d). Individual T-lymphocytes were
diﬀusely observed throughout the capsule or sometimes forming small
perivascular aggregates. In both groups, moderate numbers of blood
vessels (CD31 + positive endothelial cells; inset of Fig. 4e) were iden-
tiﬁed throughout the capsule. Areas with higher amount of collagen
tend to show reduced numbers of blood vessels, on the other hand,
higher numbers of small de novo generated blood vessels were found in
association with inﬂammatory inﬁltrates, particularly in regions close
to the inner surface of the capsule (Fig. 4e).
The interface with the device exhibited signiﬁcant diﬀerences be-
tween BI and PMC. First, BIs ﬁbrotic capsules often showed round to
elongated cells palisading along the surface. This conﬁguration is re-
miniscent of synovial metaplasia (Fig. 4e), frequently reported as a
feature of the reaction to silicone breast and joint prostheses [26]. PMC
did not show histological traits compatible with synovial metaplasia. A
subset of PMCs (2/8) cases showed ﬁbrin deposition on the surface of
Fig. 3. Gross observations associated with PMs and
PMCs. a) View of the BI ﬁbrotic capsule upon re-
moval (3-month group). BI leads are clearly trapped
in thick ﬁbrotic tissue (arrow) b) View of the PMC
ﬁbrotic capsule upon removal (3-month group). PMC
leads are clearly free of tissue (arrow) and the cel-
lulose membrane appears clear and intact. c) Inner
view of a BI pocket containing the device. The leads
are ﬁrmly surrounded by thick ﬁbrous connective
tissue (arrow). d) Inner surface of 12-month BI cap-
sule without the device. The inner capsular surface
shows multifocal hemorrhages (arrowhead). The
leads were severed in order to be released from the
surrounding ﬁbrotic capsule (arrows). The inset
shows the tracks created by the leads after removal.
e) View of an opened 12-month PMC capsule. The
device and the leads can be easily removed by
pulling out with forceps. f) The picture shows how
the BC can be easily pulled out with forceps from the
surrounding ﬁbrotic capsule.
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the cellulose. Second, small multifocal erosions of the superﬁcial cap-
sule associated with necrotic debris, ﬁbrin, and sometimes hemorrhages
were present in all BIs but only in one of the 8 PMC (Fig. 4f). Third,
multifocal hemorrhages were more common in BI (7/8) than PMC (4/8,
Fig. 4f). Fourth, multifocal regions of ﬁbroblasts haphazardly arranged
in bundles were observed (3/8) in correspondence of BIs, but not in the
PMC counterparts (Fig. 4c). Fifth, most BI (5/8) showed macrophages
containing intracytoplasmic golden/brown material interpreted as
haemosiderin, not observed in PMC. Finally, one BI showed a focal area
of mild mineralization.
Twelve months post-implantation. The ﬁbrotic capsule around BIs
was thicker than at 3 months (Fig. 6, Fig. 8). This increase in thickness
was associated with higher amount of mature collagenous bands
(stained in red with VG stain; Supplementary Fig. 5) than the 3 month
ﬁbrotic capsule and the maturation gradient (outer layers more mature
than inner layers) was more conspicuous. Areas showing a denser col-
lagenous matrix where characterized by a reduced number of ﬁbro-
blasts with no signs of cellular activation (i.e. plump nuclei). As at 3
months, BIs exhibited regions (3/7) with irregularly arranged inter-
woven bundles of ﬁbroblasts (Fig. 6c).
Like in the 3-month group, the inﬂammatory response was domi-
nated by macrophages, with moderate T-lymphocytes and occasional B-
lymphocytes, plasma cells and rare polymorphonuclear. The number of
macrophages (Fig. 7a and b) and T-lymphocytes (Fig. 7c and d) was
moderately reduced compared to the 3 month group, in particular in
those areas where the ﬁbrotic capsule showed higher maturation with
Table 2
Biocompatibility of micro-structured BC. Semi – quantitative scoring of main indicators of immune reaction. Subtotal and total scores considering the following
histological features: number of ﬁbroblasts, number of inﬂammatory cells, multinucleated giant cells, ﬁbrin deposition, synovial metaplasia, neovascularization,
hemorrhages, capsular erosion and haemosiderin. BI= native pacemaker; PMC = BC coated pacemaker; D=dorsal region; V= ventral region.
3-month group
Animal 1 2 3 4 5 6 7 8
Implant BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC
Location D V D V D V D V D V D V D V D V D V D V D V D V D V D V D V D V
Subtotal Score 15 16 7 8 10 8 4 6 12 3 7 9 9 7 5 7 11 12 6 7 9 7 7 8 12 10 5 6 6 7 5 5
Total Score 15.5 7.5 9 5 7.5 8 8 6 11.5 6.5 8 7.5 11 5.5 6.5 5
12-month group
Animal 9 10 11 12 13 14 15 16
Implant BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC BI PMC
Location D V D V D V D V D V D V D V D V D V D V D V D V D V D V D V D V
Subtotal Score 9 9 4 4 6 6 4 3 6 6 2 5 4 5 2 2 6 6 2 3 2 3 2 2 2 2 2 2 – – – –
Total Score 9 4 6 3.5 6 3.5 4.5 2 6 2.5 2.5 2 2 2 – –
Fig. 4. Histopathological observations at 3 months
follow up. a) Sub gross view of the BI capsule (arrows
indicate inner surface of the capsule). Scale bar:
500 μm. b) Sub gross view of the PMC ﬁbrotic cap-
sule with the cellulose (arrows). Scale bar: 250 μm. c)
Close up view of the BI ﬁbrotic capsule showing ﬁ-
broblasts irregularly arranged in bundles. Scale bar:
250 μm. d) Close up view of a foci of multinucleated
giant cells in a PMC ﬁbrotic capsule. Scale bar:
100 μm. e) Close up view of the inner BI ﬁbrotic
capsule with superﬁcial synovial metaplasia (black
arrows), superﬁcial inﬂammation (green arrows) and
neovascularization (arrowheads). Scale bar: 100 μm.
Inset: CD31 staining to reveal neovascularization.
Scale bar: 100 μm. f) Close up view of the superﬁcial
BI capsule with a focal erosion associated with ﬁbrin
deposition hemorrhages and inﬂammation (arrow),
and areas neovascularization (arrow heads). Scale
bar: 250 μm. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to
the Web version of this article.)
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Fig. 5. Immunohistochemical examination at 3-
month post implantation of BI (left panel) and PMC
(right panel). A and B) Iba-1 antibody shows nu-
merous macrophages diﬀusely inﬁltrating the inner
layers of the ﬁbrotic capsule. The BI capsular surface
in contact with the medical device exhibits synovial
metaplasia with small to moderate numbers Iba-1
positive cells (arrows, A). The PMC capsular surface
in contact with the cellulose shows a thin rim of in-
ﬁltrating macrophages (arrows, B). C and D) CD3
antibody shows small to moderate numbers of T-
lymphocytes diﬀusely inﬁltrating the inner layers of
the ﬁbrotic capsule including small numbers in the BI
synovial metaplasia (arrows, C) and a small rim of
positive cells along the PMC capsular surface in
contact with the cellulose (arrows, D). E and F) CD20
antibody shows small numbers of B-lymphocytes
diﬀusely scattered throughout the inner layers of the
ﬁbrotic capsule of BI (arrow, E) and PMC (arrow, F).
Scale bar: 100 μm.
Fig. 6. Histopathological observations at 12 months
follow up. a) Sub gross view of the BI capsule (arrows
indicate inner surface of the capsule). Scale bar:
1mm. b) Sub gross view of the PMC ﬁbrotic capsule
with the cellulose (arrows). Scale bar: 250 μm. c)
Close up view of a BI ﬁbrotic capsule with multifocal
to coalescing foci of inﬂammation (arrows) and ﬁ-
broblasts irregularly arranged in bundles. d) Close up
view of the inner BI ﬁbrotic capsule with large
amount of ﬁbrin deposition. Scale bar: 250 μm Inset:
PTAH staining to reveal ﬁbrin. Scale bar: 100 μm. e)
Close up view of the superﬁcial BI capsule with a
focal erosion associated with ﬁbrin deposition and
hemorrhages (arrows). Scale bar: 250 μm. f) Close op
view of a calciﬁed focus in the cellulose in contact
with the ﬁbrotic capsule. Scale bar: 250 μm.
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abundant collagenous deposition. Moreover, at this later time point,
multinucleated giant cells were markedly less numerous than at the 3
months, with only one PMC animal showing small groups. Synovial
metaplasia and ﬁbrin deposition (Fig. 6d) were detected around BIs (2/
7 and 5/7; respectively). Similarly to the 3-month group, moderate
numbers of blood vessels were observed throughout the capsule with
lower density in collagen dominated areas and higher density in re-
active/inﬂamed areas often close to the inner surface. The band of ﬁ-
brin deposited at the capsular surface was signiﬁcantly thicker than at 3
months (Fig. 6d). Superﬁcial capsule erosion was observed both in BIs
(2/7) and PMC (1/7; Fig. 6e) as well as tissue mineralization (1/7 BIs
and 2/7 PMC; respectively). Mineralization was more prominent in
PMCs where it aﬀected the outer BC layer (in contact with the ﬁbrotic
capsule). The reaction was characterized by deposition of hyperba-
sophylic crystalloid to granular material. It did not extend throughout
the entire BC layer and did not compromise the membrane integrity
(Fig. 6f).
2.5. Quantitative evaluation of ﬁbrotic tissue build-up
Each of the explanted tissue section containing the devices was
processed as described in detail in Materials and Methods section with
the aim of assessing the thickness of the layer of newly formed ﬁbrotic
tissue (Fig. 8a and b), the markers of foreign body reaction and ongoing
inﬂammation. The ﬁbrotic capsule thickness was signiﬁcantly smaller
around PMCs at 3 months compared to BI (0.87 ± 0.28mm vs.
1.60 ± 0.44mm; p < 0.05, 38% average reduction). At 12 months
this diﬀerence further increased (0.98 ± 0.43mm vs.
2.89 ± 0.90mm; p < 0.001, 66% average reduction). The BI capsule
was on average in the range of few millimetres, indicating a prompt and
continuous response of the animals to the implantation of the devices.
The formation of ﬁbrotic tissue in the pocket was signiﬁcantly reduced
in the presence of BC membranes, with an average thickness reduction
of 66% (Fig. 8c). Interestingly, the maximum reduction achieved was
approximately 80% and occurred in animals showing the highest values
of thickness around BI implant.
3. Discussion
Rising incidence of CIED implantation combined with increased life
expectancy yields higher implant prevalence, which is associated with a
higher burden of device replacement and upgrade/revision surgery
[27]. The number of generator exchange and upgrade procedures can
be expected to rise. Therefore, the recommendation for lifelong implant
must consider - among the risk factors - the hazards related to the re-
placement of the generator or an upgrade/revision procedure. The
mitigation of these risks can follow two diﬀerent paths: a signiﬁcant
eﬀort has to be made in research and development to extend the
longevity of the implantable batteries. Solutions for minimizing com-
plications related to the device pocket must be found [6]. An additional
drawback related to re-operation is the signiﬁcantly higher rate of in-
fection after replacement procedures [28]. Pocket related complication
rates after generator exchange or upgrade/revision surgery are con-
siderable [6]. Therefore, every concept simplifying the dissection of
device pockets will show a positive eﬀect on complication rates.
The importance of the device pocket as a source of complications is
reﬂected by the clinical introduction of a resorbable, antibacterial en-
velope (TYRX, Medtronic, USA) to reduce the rate of pocket infections.
The results of the WRAP-IT study, a prospective randomized trial on the
eﬃcacy of the antibacterial protection, brought further clariﬁcation on
the beneﬁcial eﬀects of TYRX [29], showing signiﬁcant reduction of
occurrence of infection with the use of the envelope. A diﬀerent
Fig. 7. Immunohistochemical examination at 12-
month post implantation of BI (left panel) and PMC
(right panel). A and B) Iba-1 antibody shows mod-
erate macrophages diﬀusely inﬁltrating the inner
layers of the BI (A) and PMC ﬁbrotic capsule (B) C
and D) CD3 antibody shows small to moderate
numbers of T-lymphocytes diﬀusely inﬁltrating the
inner layers of the BI (C) and PMC ﬁbrotic capsule
(D). E and F) CD20 antibody shows occasional B-
lymphocytes diﬀusely scattered throughout the inner
layers of the ﬁbrotic capsule of BI (arrow, E) and
PMC (arrow, F). Scale bar: 100 μm.
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approach to CIEDs wrapping is provided by Cangaroo (Azyio Biologics,
USA). The Cangaroo envelope is made of decellularized porcine extra-
cellular matrix, which is remodelled by the host into a healthy, vas-
cularized pocket supporting the device and reducing the risk of mi-
gration. Up to date, no clinical data are available on the eﬀectiveness of
this procedure [30].
Other surgical protocols, including abdominal surgery, similarly
adopt adhesion barriers (e.g. Interceed, Sepraﬁlm, etc.) to prevent
tissue-to-tissue adhesion upon healing. These gels or ﬁlms, comprising
oxidised regenerated cellulose or hyaluronate carboxymethylcellulose,
establish an intervening separation between the operative surfaces
within the abdomen [31]. They must be retained until complete healing
and eventually reabsorb without inducing foreign body reaction.
Compared to the substrate presented in this work, these devices present
signiﬁcant technological diﬀerences and a diﬀerent intended use.
Importantly, neither any of the currently available envelopes for
CIEDs nor any of the above-mentioned adhesion barriers speciﬁcally
targets foreign body response and ﬁbrotic tissue deposition. The ap-
proach presented in this work is therefore innovative, as it consists of a
non-resorbable material exploiting a new mode of action through the
combination of an antifouling material and a rationally developed
surface topography.
The insertion of a non-adhesive, non-resorbable and simultaneously
well-tolerated interface enables the operator to easily access a clean
pocket, simplifying the exchange or upgrade or revision procedure.
After the generator pocket is opened in such procedures, there is a
frequent need for extensive and time consuming dissection of the leads
from ﬁbrotic scar tissue [32], while the tested BC membrane makes this
procedure simply unnecessary. The elimination of the need for the lead
dissection, reduction of surgical trauma to the pocked and will lead to a
relevant decrease of post-operative pocket hematomas. Pocket hema-
tomas are a known risk factor for subsequent pocket infection (Odd
Ratio= 8.46 (4.01–17.86)) [33]. Taken together, the easiness of re-
operation and the drastically improved accessibility to the site of the
implant constitute a parameter of increasing importance in the deﬁni-
tion of successful therapeutic strategy.
On the other hand, the quality of the interaction between the im-
plant and the surrounding tissue is what determines the long-term
comfort of the patient and contributes to the ultimate success of a
surgical procedure comprising a foreign body implant. For numerous
implants in soft tissue, foreign body reaction constitutes one of the
major causes of discomfort, pain and ultimately revisions [34].
The establishment of a rationally designed, stable interface between
the body and the implant is a viable strategy to minimize the compli-
cations related to foreign body response. The performance of such a
membrane depends on the constitutive properties of the material, in
this case BC, and on the capability to speciﬁcally tailor the surface to-
pography, an independent physical parameter, in order to elicit speciﬁc
responses in human cells [21]. In this study, the presence of micro-wells
distributed on a hexagonal lattice on a layer of BC aims at the reduction
of the adhesion of immune cells and ﬁbroblasts, responsible for the
deposition of the new collagen matrix and the creation of the typical
dense ﬁbrotic tissue [24]. As reported earlier [24], surface topography
proved to successfully inﬂuence adhesion of cells in vitro and the same
eﬀect seems to be reproduced in vivo, if quantiﬁed through the thick-
ness of the newly deposited tissue. Brieﬂy, the mode of action of such a
topography is based on the concept that an isotropic distribution of
topographical features on a substrate, on the scale of the cell, creates
unfavourable conditions for adhesion.
The thickness of the ﬁbrotic capsule is an important physical
parameter to describe the advancement of the foreign body response,
but this has to be coupled to biological reporters, especially in-
ﬂammation markers, to provide a comprehensive description of the
status quo after 3 and 12 months. Semi-quantitative histological analysis
Fig. 8. Histological sampling and thickness measurements: a) Representative sampling for tissue thickness quantiﬁcation around the BI. b) Quantiﬁcation and
statistical comparison of the measurements of the overall thickness of the ﬁbrotic tissue layer surrounding the BI and PMC at 3 months follow up. c) Quantiﬁcation
and statistical comparison of the measurements of the overall thickness of the ﬁbrotic tissue layer surrounding the BI and PMC at 12 months follow up. The
population means are reported as a horizontal dash-dotted line The number of measurements is reported as number n’ and the number of independent experiments is
reported as the number n. Signiﬁcant diﬀerences between the population means are indicated by asterisks (* for p < 0.05 and *** for p < 0.001).
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revealed that the ﬁbroinﬂammatory reaction elicited by BI and PMCs
had comparable morphological features, but with a drastic reduction of
the thickness of ﬁbrotic capsules in the latter.
While clearly establishing the stability, safety and performance of
the presented micro-engineered BC anti-ﬁbrotic protection, in a clini-
cally relevant large animal model, this study still has limitations. These
are of intrinsic nature. Revision and upgrade surgeries are typically
performed at> 1 year after the original implant, in humans, which is
longer than what could be reproduced in the animal study at hand.
Speciﬁc traits of inﬂammatory and foreign body reaction in cardio-
vascular patients similarly not reproduced in healthful individuals,
particularly aﬀecting the extent and nature of ﬁbrotic tissue formation.
Altogether, this work provides suﬃcient in vivo evidence for the anti-
ﬁbrotic eﬃcacy of a protective layer made of micro-engineered BC,
opening to the translation of this innovative medical device.
4. Materials and methods
4.1. Membrane fabrication and surface microstructuring
Surface micro-structured 20 cm×10 cm biosynthesized cellulose
(BC) membrane segments were fabricated using Guided-Assembly Bio-
Lithography (GAB), as previously reported [25]. Brieﬂy, cellulose was
synthesized by a strain of the bacterium Acetobacter xylinum in static
culture and with an elastomeric microstructured mold ﬂoating at the
liquid-air interface. The BC membrane was made of a three-dimensional
network of randomly arranged cellulose nanoribbons, resulting in the
formation of a multi-layer hydrogel with high porosity (Fig. 1a).
Through GAB, the surface of the BC membrane was natively micro-
structured with approximately 2 μm deep micro-wells distributed in a
centered-hexagonal pattern with characteristic length of 20 μm
(Fig. 1b). The diameter of each well was deﬁned as half of the center-to-
center distance, namely 10 μm. Importantly, GAB produced a higher
degree of order in the nanoscopic arrangement of the ribbons in close
proximity of the micro-wells, clearly delineating the surface micro-
features [24,25]. The BC membranes were harvested after 1 week of
incubation at 27 °C and the bacterial content was removed by 1M
NaOH at 90 °C for 8 h. The pH was ﬁnally balanced with a series of
washings (≥8×1 h washings) in de-ionized (DI) water. After pre-
liminary puriﬁcation, the membranes were treated according to a
puriﬁcation protocol consisting of three 24 h washings in aqua ad In-
iectabilia (Braun, Germany) to minimize the residual endotoxin content
and remove traces of potentially cytotoxic, pyrogenic organic residues.
Membranes had a residual endotoxin content< 20 EU/device, as pre-
scribed for fully implantable medical devices.
4.2. Endotoxin measurement
Biosynthesized cellulose membrane (20 cm2) was cut using a de-
pyrogenated set of scissors or a scalpel, making sure to cut the sample
on a depyrogenated stainless steel (SS) surface. The samples were
transferred into a Whirlpak Bag or apyrogenic glassware (Erlenmeyer
ﬂask 250ml) using depyrogenated forceps. 40mL of LRW (LAL Reagent
Water) were added to the Whirlpak Bag or apyrogenic glassware
(Erlenmeyer ﬂask 250ml) and the container was placed into an in-
cubator (36–38 °C) or water bath shaker for at least 15min. Shaking the
initial sample inside of the incubator or water bath shaker. A portion of
the extract was transferred into a depyrogenated conical tube. 25 μl
aliquots of the endotoxin extract ﬂuid were transferred into each of the
four wells of the PTS cartridge, ensuring no bubbles were present in the
well at the beginning of the assay.
4.3. Mechanical characterization of the cellulose membrane
Membranes were characterized according to ISO 527-3
(Determination of tensile properties) using a uniaxial testing tool
(Hounsﬁeld H5KT) using ASTM D638.1 dumbbell shaped samples. The
testing speed was set to 50mm/min. The variables measured were
strength (stress at the ﬁrst local maximum during the test), strain at
strength (strain at which the strength is reached), stress at break (stress
at which the specimen breaks) and strain at break, (strain at which the
break occurs).
4.4. Membrane preparation
The membranes were carefully placed into the plastic blister with
the non-structured side facing upwards, in order to be ready for use
upon opening of the container. Always operating in sterile conditions,
the container was placed into a second blister and sealed. After sealing,
the membranes were steam sterilized (121 °C, 15min).
4.5. Experimental animals
The animals used in this study were adult female minipigs weighing
approximately 40 kg at the time of implantation. The entire study was
performed in the framework of the EU directive 2010/63, the German
animal protection law and the animal experimentation regulation
(TschVersV) after permission granted by license G 0116/17 issued by
the LaGeSo Berlin. Details in the Surgical preparation, coated device im-
plantation and postsurgical monitoring, Housing and husbandry and Animal
Welfare sections of Materials and Methods are taken from the Standard
Operating Procedures of the Animal Facility (FEM) of the Charité-
Universitätsmedizin Berlin and reported as requested by the ARRIVE
Guidelines.
4.6. Animal study design
Sixteen (n= 16) animals were included in the study. In order to
reduce the number of animals and considering the local eﬀects of the
formation of the ﬁbrotic tissue, each animal received one cellulose
coated pacemaker (PMC), one native pacemaker (BI). Equivalent ana-
tomical sites were chosen for the implantation of the test and control
specimens, with the test implant site contralateral to the control im-
plant site, thereby minimizing the number of animals as each animal
served as its own control.
The study was undertaken in four consecutive steps: acclimatization
of the animals in the animal facility, simultaneous implantation of the
BI, PMC, monitoring (observation, physical inspection, blood sam-
pling), followed by explant and histopathological analysis.
A ﬁrst group of eight (n= 8) subjects was followed up for a period
of 3 months, while the remaining eight (n=8) subjects were followed
up for 12 months. One animal was sacriﬁced at 4 months after im-
plantation due to a persistent lameness and back pain after socialisation
trial with another animal from the study. Section of the animal showed
no indication that the clinical symptoms were caused by the im-
plantation or the tested material.
4.7. Housing, husbandry and animal welfare
On arrival, all animals were examined and were given an acclima-
tization period of at least 7 days prior to the experiment. The animals
were then kept in groups of 2–4 per stable compartment, which each
provided a shelter for retraction, automatic water drinker and en-
tertainment toys. Animals were fed twice per day (morning and eve-
ning) with dry pelleted food (15–20 g/kg/day per animal). The room
temperature was constantly at 20 ± 2 °C at a relative air humidity of
around 55 ± 10%. The artiﬁcial light was turned on from 8:00 a.m.
until about 6:00 p.m., but roof windows ensured suﬃcient natural
daylight intake. Prior to the experiment, the general condition of each
animal was monitored by the animal care takers twice a day and at least
two times a week by a veterinarian. Once a week each minipig was
allured with food onto a scale to determine its current weight.
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4.8. Surgical preparation, coated device implantation and postsurgical
monitoring
The animals were fasted for at least 12 h before surgery. In order to
reduce stress and to sedate the animals prior to induction of anaes-
thesia, they were pre-medicated in the stable, with an intra-muscular
injection of 25mg/kg Ketamin, 3,5mg/kg Xylazin, 3 mg/kg Azaperon
and 0,25 ml/10 kg Atropinsulfate. After loss of righting reﬂex, animals
were transported to the animal operation theatre, where oxygen was
applied over a mask and a venous catheter was placed in the ear-vein.
Propofol was applied (bolus 1–2mg/kg, intra-venous) to achieve re-
laxation and swallow-reﬂex diminishment suﬃcient for intubation.
After intubation anaesthesia was deepened giving a further propofol
bolus to stop spontaneous breathing. Furthermore, a Fentanyl bolus was
applied for analgesia. Anaesthesia was maintained by positive pressure
respiration of Isoﬂurane (1,2% - 1,8%) in pure oxygen. For in-
traoperative analgesia Fentanyl was applied continuously with 1–4 μg/
kg/h. During the whole surgical procedure, infusion solution was ap-
plied continuously. The operation area was washed and shaved, and a
urine catheter was placed. During the entire preparation procedure, the
status of the animal was monitored using pulse-oximetry, ECG, non-
invasive blood pressure monitoring and capnometry.
The ventral neck, shoulder and chest of the pig were prepped and
draped surgically using 10% povidone-iodine and 80% alcohol rinse.
Sterile surgical drapes were used to entirely cover the animal while
keeping the shoulder/chest area adequately exposed.
Standard sterile operative techniques (equivalent to those for
human implantation) were used, including change of gloves and in-
struments at each implant placement, ensuring haemostasis before
implant insertion, minimizing implant handling, and avoiding contact
of the implant with the animal skin.
After skin incision and preparation of a subcutaneous device pocket,
an active ﬁxation bipolar pacemaker lead (Medtronic, USA) was im-
planted transvenously via the internal jugular vein and placed in the
right atrium under ﬂuoroscopic guidance. The lead was connected to a
single chamber pacemaker device (Medtronic, USA). The BC membrane
was transferred to the operating table inside its packaging, preserving
the orientation with the unstructured side of the membrane facing
upwards. The generator was placed above the coiled-up leads, in the
same fashion to what is commonly performed according to implanta-
tion guidelines. The pacemaker and the proximal part of the leads were
wrapped by the cellulose membrane in a manner that the device and
the lead were completely covered by the cellulose membrane.
The cellulose covered device was then inserted into the sub-
cutaneous pocket on the left and right lateral chest wall of the animal.
The surgical wound was closed in two layers: absorbable sutures, 3–0
Vicryl plus and 4-0 undyed Monocryl (Ethicon, USA) were used for the
sub-cutaneous and intra-cutaneous sutures, respectively. OpSite spray
(Smith&Nephew, USA) was applied over the operative wounds to re-
duce the risk of exogenous contamination of the wound. The pacemaker
systems were left in situ for a time period of 3 or 12 months. For
postoperative pain relief Buprenorphin was injected 0.1 mg/kg i.m. and
a fentanyl patch was applied releasing fentanyl for three consecutive
days.
During the entire experimental procedure until the animal was fully
awake, the animal was monitored using pulse-oximetry, ECG, invasive
arterial blood pressure measurement, capnometry, respiration counter,
arterial and venous blood gas analyses. Based on those parameters,
anaesthesia was adjusted.
Once the surgical procedure was completed, the protective wound-
draping was applied. After regaining consciousness (swallowing,
spontaneous movement etc.) the animal was brought back into its
stable and monitored hourly for the ﬁrst 2–4 h after the surgery.
4.9. Retrieval and histopathological analysis of the devices
Macroscopic and histological examinations were performed to
evaluate the biological response to the implanted BIs and PMCs. PMCs
ﬁndings were compared to that observed in the control PMs.
Immediately after sacriﬁce, the animals underwent a partial necropsy to
remove the implants and examine macroscopically the surrounding soft
tissues. The PMs were explanted together with the surrounding ﬁbrotic
capsule and suﬃcient unaﬀected tissue and were examined for any
gross anomalies, such as hyperaemia and hemorrhages. The presence,
amount and nature of any ﬂuid within the implant cavity or any ma-
terial adhered to the BI were recorded. The inner surface of the capsule
was inspected at the time of necropsy and after formalin ﬁxation of the
samples. Macrophotography was used to document relevant observa-
tions. Excised PMs and the surrounding soft tissues were ﬁxed for 72 h
in adequate amounts of 10% neutral buﬀered formalin (Formaﬁx,
Switzerland). Brieﬂy, each implant capsule was incised along the
midline and the PMs gently removed as a whole, although cutting of the
leads, strongly embedded in the surrounding capsular soft tissues, was
necessary in some BIs to allow removal of the devices.
The histological sections (3–5 μm thick) were prepared and routi-
nely stained for hematoxylin and eosin (HE) and van Gieson (VG) for
the histological examination and collagen quantiﬁcation respectively.
Phospho-Tungstic Acid Hematoxylin (PTAH) special stain was selec-
tively used in some cases to stain ﬁbrin. Immunohistochemical eva-
luation was also performed to detect ionized calcium binding adaptor
molecule 1 (Iba-1/macrophages), CD3 (T-lymphocytes), CD20 (B-lym-
phocytes) and CD31 (endothelial cells). Detailed information about the
antibodies, antigen retrieval and detection methods are provided in
Methods Table 1. For Iba1, CD20 and CD31 antibodies Dako autostainer
(Dako, Glostrup, Denmark) system was used whereas the Discovery XT
autostainer (Ventana Medical System, Inc, Tucson, Arizona, USA)
system was used for the CD3 antibody. Brieﬂy, antigen retrieval was
performed in all the antibodies using citrate buﬀer (pH 6) at 98 °C for
20min or EDTA buﬀer (pH 9) at 98° for 20min and CC1 buﬀer (pH
8.4). Subsequently, endogenous peroxidase activity was quenched with
hydrogen peroxidase for 10min. Primary antibodies were incubated for
1 h followed by secondary antibody application. Diﬀerent detection kits
were used (Methods Table 1). Finally, sections were counterstained
with hematoxylin for 40 s and mounted. Pig lymph node served as
positive control for Iba1, CD3 and CD20 antibodies and lung tissue was
used for CD31. Two negative controls were used, one with omission of
the primary antibody and one with an isotype-matched irrelevant an-
tibody.
Methods Table 1
Antibodies and immunohistological methods. Abbreviations: Iba-1, ionized
calcium binding adaptor molecule 1; CD, cluster of diﬀerentiation; citrate, ci-
trate buﬀer pretreatment; EDTA, EDTA pretreatment; CC1, cell conditioning 1
pretreatment; mAb, monoclonal antibody; pAb, polyclonal antibody.
Antigen Antibody
(clone)
Source Dilution Pre-treat-
ment
Detection
Iba-1 Rabbit pAb
(019–19741)
Wako 1:750 Citrate Envision Rabbit
(Dako)
CD3 Mouse mAB
(M725401-2)
Dako 1:100 CC1 ChromoMap DAB
(Ventana Medical
Systems)
CD20 Rabbit pAb
(RB-9013-P0)
Thermo
Scientiﬁc
1:700 n/a Envision Rabbit
(Dako)
CD31 Rabbit pAb
(sc-1506)
Santa
Cruz
1:1500 EDTA Envision Rabbit
(Dako)
Histopathological features were scored in a blind fashion according
to a semi-quantitative scoring system suggested in Annex E of
International Standards Organization (ISO) 10993-6-2016, which takes
into consideration - among others - the extent of ﬁbrosis/ﬁbrous
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capsule, the extent and nature of the associated inﬂammatory reaction,
the presence and extent of degeneration/necrosis and the degree of
vascularization. According to these premises, the following histo-
pathological features were evaluated: number of ﬁbroblasts, number of
inﬂammatory cells, presence of multinucleated giant cells, ﬁbrin de-
position, synovial metaplasia, neovascularization, hemorrhages, cap-
sular erosion and haemosiderin (Supplementary Table 1). Each cate-
gory was scored with a number that represented the severity of the
histological change: 0= not present; 1=mild; 2=moderate; 3= se-
vere. A total score representing the severity of biological response to the
device was obtained by summing the scores of each histological feature
(Table 1). The extent of ﬁbrosis was further analysed using a histo-
morphometric approach, as detailed in the next paragraph. All HE-
stained slides were scanned using a digital slide scanner (NanoZoo-
merXR C12000, Hamamatsu, Japan) and images were taken using
NDP.view2 viewing software (Hamamatsu).
4.10. Image Analysis
Lateral size or projected diameter of the ﬁbers, was calculated from
SEM images using the measurement tool of ImageJ.
For the quantitative assessment of the ﬁbrotic tissue thickness, the
digital images were imported into ImageJ (National Institute of Health,
USA) using the NDPITools plugin [35].
The ﬁbrotic tissue thickness was determined using ﬁrst the
“Freehand line” tool to manually select the ﬁbrotic tissue layer. The
selected regions were exported as regions of interest and then the
“Measurements” tool of ImageJ was used to obtain the thickness value
in cm. The measurement protocol foresaw taking 36 individual thick-
ness measurements per implant analysed. The independent measure-
ments were then averaged in order to obtain the mean ﬁbrotic tissue
thickness for each independent position.
Visiopharm software (Visiopharm Integrator System, Version 5.0.4.
1382; Visiopharm, Horsholm, Denmark) was used to label the collagen
ﬁbres stained with VG special stain. First, manual annotations were
introduced to select the ﬁbrotic capsule and subsequently threshold
classiﬁcation method was applied to label the collagen bands.
4.11. Statistical analysis
Statistical comparison of population means was performed using a
paired Student's T-test (after data assessment for Normality) or a non-
parametric Paired-sample Wilcoxon Signed Rank test. The eﬀect was
quantiﬁed on a single scalar parameter (i.e. thickness of ﬁbrotic tissue)
measured in two conditions (i.e. test condition with BC protection and
control bare implant) in each experimental animal. The total number of
measurements is shown in the upper or lower right-hand corner of the
presented graphs in Fig. 8. For box plots the size depicts the measured
standard error of the mean and the whiskers the standard deviations of
the populations.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.biomaterials.2019.119583.
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